This inventor holds 1 USPTO granted patent and 4 published patent applications and 1 EPO patent. Top assignee: Entelos, Inc.. Active years: 2009.
Company Filing History:
Years Active: 2009
Title: Mark Fielden - Innovator in Renal Tubule Injury Prediction
Introduction
Mark Fielden is an accomplished inventor based in Mountain View, CA (US). He has made significant contributions to the field of medical diagnostics, particularly in predicting renal tubule injury. His innovative work has the potential to improve patient outcomes through early detection and intervention.
Latest Patents
Mark Fielden holds a patent for "Reagent sets and gene signatures for renal tubule injury." This invention discloses reagent sets and gene signatures that can predict the onset of renal tubule injury in a subject. The invention provides a necessary set of 186 genes that are useful for generating signatures of varying size and performance, capable of predicting the onset of renal tubule injury. Additionally, it offers methods, apparatuses, and reagents that are useful for predicting future renal tubule injury based on the expression levels of genes in the signatures. In one particular embodiment, the invention provides a method to predict whether a compound will induce renal tubule injury using gene expression data from sub-acute treatments.
Career Highlights
Mark Fielden is currently associated with Entelos, Inc., where he continues to advance his research and innovations. His work is pivotal in the development of diagnostic tools that can significantly impact patient care.
Collaborations
Mark has collaborated with notable colleagues such as Georges Natsoulis and Kurt Jarnagin, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Mark Fielden's contributions to the field of renal tubule injury prediction exemplify the impact of innovative thinking in medical diagnostics. His patent and ongoing work at Entelos, Inc. highlight the importance of early detection in improving patient outcomes.